Free Trial

Jazz Pharmaceuticals (JAZZ) Competitors

Jazz Pharmaceuticals logo
$135.39 +1.43 (+1.07%)
Closing price 02/18/2025 04:00 PM Eastern
Extended Trading
$134.98 -0.41 (-0.31%)
As of 07:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

JAZZ vs. RPRX, CORT, PRGO, SUPN, PCRX, OMER, NKTR, ASMB, CPIX, and LLY

Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry.

Jazz Pharmaceuticals vs.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking.

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 4.2% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 18.9% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Jazz Pharmaceuticals had 5 more articles in the media than Royalty Pharma. MarketBeat recorded 14 mentions for Jazz Pharmaceuticals and 9 mentions for Royalty Pharma. Jazz Pharmaceuticals' average media sentiment score of 0.97 beat Royalty Pharma's score of 0.71 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Royalty Pharma
4 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Royalty Pharma has a net margin of 50.53% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Royalty Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals11.60% 29.30% 9.72%
Royalty Pharma 50.53%24.65%14.44%

Jazz Pharmaceuticals currently has a consensus target price of $180.33, indicating a potential upside of 33.20%. Royalty Pharma has a consensus target price of $41.67, indicating a potential upside of 26.84%. Given Jazz Pharmaceuticals' higher probable upside, equities analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.93
Royalty Pharma
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

Jazz Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

Jazz Pharmaceuticals received 802 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 80.77% of users gave Jazz Pharmaceuticals an outperform vote while only 67.92% of users gave Royalty Pharma an outperform vote.

CompanyUnderperformOutperform
Jazz PharmaceuticalsOutperform Votes
1126
80.77%
Underperform Votes
268
19.23%
Royalty PharmaOutperform Votes
324
67.92%
Underperform Votes
153
32.08%

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Royalty Pharma is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$3.99B2.05$414.83M$7.1019.07
Royalty Pharma$2.36B8.22$1.13B$1.9317.02

Summary

Jazz Pharmaceuticals beats Royalty Pharma on 12 of the 19 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JAZZ vs. The Competition

MetricJazz PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.19B$6.87B$5.77B$9.20B
Dividend YieldN/A2.90%5.29%3.99%
P/E Ratio19.079.4226.4819.51
Price / Sales2.05260.31448.6069.98
Price / Cash4.3175.4646.0638.90
Price / Book2.285.477.235.07
Net Income$414.83M$123.25M$3.19B$222.54M
7 Day Performance-0.04%1.73%1.41%2.13%
1 Month Performance11.73%1.38%3.50%1.63%
1 Year Performance6.79%-0.12%20.70%16.41%

Jazz Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JAZZ
Jazz Pharmaceuticals
4.9833 of 5 stars
$135.39
+1.1%
$180.33
+33.2%
+6.8%$8.10B$3.83B19.072,800Upcoming Earnings
RPRX
Royalty Pharma
4.8522 of 5 stars
$32.36
-0.3%
$41.67
+28.8%
+9.8%$19.07B$2.36B16.7780
CORT
Corcept Therapeutics
4.4116 of 5 stars
$72.72
-1.2%
$88.25
+21.4%
+219.7%$7.62B$482.38M57.71300Upcoming Earnings
PRGO
Perrigo
4.9749 of 5 stars
$24.48
-1.3%
$35.00
+43.0%
-24.6%$3.34B$4.66B-20.939,140
SUPN
Supernus Pharmaceuticals
3.0847 of 5 stars
$39.11
-1.1%
$46.50
+18.9%
+39.9%$2.16B$607.52M36.55580Analyst Downgrade
News Coverage
PCRX
Pacira BioSciences
3.4217 of 5 stars
$25.44
-4.1%
$22.78
-10.5%
-9.1%$1.17B$674.98M-12.53720
OMER
Omeros
3.5201 of 5 stars
$9.18
+0.7%
$22.50
+145.1%
+91.0%$531.98MN/A-3.97210
NKTR
Nektar Therapeutics
4.2133 of 5 stars
$0.98
+10.2%
$4.08
+315.6%
+48.9%$181.25M$93.14M-1.17220Gap Up
High Trading Volume
ASMB
Assembly Biosciences
4.3319 of 5 stars
$13.02
+6.6%
$35.00
+168.8%
+9.1%$82.81M$7.16M0.00100Positive News
High Trading Volume
CPIX
Cumberland Pharmaceuticals
1.4857 of 5 stars
$5.15
+11.0%
N/A+129.5%$72.31M$39.55M-6.6980Gap Up
LLY
Eli Lilly and Company
4.8589 of 5 stars
$844.82
-3.1%
$997.50
+18.1%
+9.6%$802.01B$45.04B72.1543,000Positive News

Related Companies and Tools


This page (NASDAQ:JAZZ) was last updated on 2/19/2025 by MarketBeat.com Staff
From Our Partners